Funding
Seed · Biotech

Goldenrod Therapeutics raises $6.5m seed round

Ataxia Ventures and Fannin Partners participated in financing for brain-penetrant therapies.

Updated Oct 16, 2026By RoundOS Funding desk

Goldenrod Therapeutics raised $6.5 million in seed financing on June 4, with participation from Ataxia Ventures and Fannin Partners. The company develops brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways.

Funding history

Seed · This round$6.5M

Sources

  1. Goldenrod Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related